Skip to main content
All lobbying filings

Tiber Creek Group

Tiber Creek Group filed a Q2 report for Tiber Creek Health Strategies, Inc. (On Behalf of Eli Lilly and Company) on July 19, 2026, reporting $80,000 in lobbying income.

Lobbying for Tiber Creek Health Strategies, Inc. (On Behalf of Eli Lilly and Company) · Pharmaceutical company.

As filed: TIBER CREEK GROUP for TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY).

All filings by Tiber Creek Group · Everything Tiber Creek Health Strategies, Inc. (On Behalf of Eli Lilly and Company) has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 19, 2026
Income
$80,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 3

Issues related to drug pricing and reimbursement for prescription drugs; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the One Big Beautiful Bill Act (PL 119-21).

Issues related to drug pricing; Issues related to reimbursement of insulin products; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to compounding and H.R. 6509 - Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.

Issues related to intellectual property; Issues related to S. 1041 - Affordable Prescriptions for Patients Act; Issues related to patent thickets; Issues related to S. 1096 - Preserve Access to Affordable Generics and Biosimilars Act; Issues related to S.2658 - Medication Affordability and Patent Integrity Act.

 Bills named in this filing 4
  • H.R. 6509
    SAFE Drugs Act of 2025
  • S. 1041
    Affordable Prescriptions for Patients Act
  • S. 1096
    Preserve Access to Affordable Generics and Biosimilars Act
  • S. 2658
    Medication Affordability and Patent Integrity Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem